Harrow Inc(HROW) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:05 PM ET (Korea 10/28 05:05)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1 | Insider Own | 15.18% | Shs Outstand | 37.5M | Perf Week | 3.56% |
| Market Cap | 1.09B | Forward P/E | 13.33 | EPS next Y | 3072.74% | Insider Trans | 0.07% | Shs Float | 31.8M | Perf Month | -8.01% |
| Enterprise Value | 1.31B | PEG | - | EPS next Q | 0.19 | Inst Own | 57.56% | Short Float | 23.51% | Perf Quarter | -24.84% |
| Income | -0.04B | P/S | 3.95 | EPS this Y | 47.62% | Inst Trans | 3.21% | Short Ratio | 13.13 | Perf Half Y | -28.19% |
| Sales | 0.28B | P/B | 71.69 | EPS next 5Y | - | ROA | -9.77% | Short Interest | 7.47M | Perf YTD | -40.67% |
| Book/sh | 0.41 | P/C | 12.99 | EPS past 3/5Y | 35.17% -1.53% | ROE | -114.8% | 52W High | -47% ($54.85) | Perf Year | -23.98% |
| Cash/sh | 2.24 | P/FCF | 217.09 | Sales past 3/5Y | 45.39% 40.99% | ROIC | -11.82% | 52W Low | 7.83% ($26.96) | Perf 3Y | 112.04% |
| Dividend Est. | - | EV/EBITDA | 48.47 | EPS Y/Y TTM | -244.96% | Gross Margin | 73.28% | Volatility(W/M) | 4.02% 4.72% | Perf 5Y | 204.4% |
| Dividend TTM | - | EV/Sales | 4.74 | Sales Y/Y TTM | 21.05% | Oper. Margin | 2.07% | ATR (14) | 1.35 | Perf 10Y | 968.75% |
| Dividend Ex-Date | - | Quick Ratio | 2.08 | EPS Q/Q | -459.56% | Profit Margin | -13.51% | RSI (14) | 41.22 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.24 | Sales Q/Q | 10.85% | SMA20 | -0.2% ($29.13) | Beta | 0.16 | Target Price | $65 |
| Payout | - | Debt/Eq | 19.79 | Earnings | 2026/11/9 | SMA50 | -13.41% ($33.57) | Rel Volume | 1.12 | Prev Close | $28.95 |
| Employees | 373 | LT Debt/Eq | 19.72 | EPS/Sales Surpr. | -157.27% 0.44% | SMA200 | -24.74% ($38.63) | Avg Volume(3M) | 0.57M | Price | $29.07 |
| IPO | 2007/4/24 | Option/Short | Yes/Yes | Trades | 6310 | Volume | 635,462 | Change | 0.41% |
👁️ Harpoon HROW is a US specialty pharmaceutical company focused on ophthalmology (eye care). Its core business is the development and commercialization of ophthalmic pharmaceuticals, and through ImprimisRx, its ophthalmic-focused compounding business, it supplies prescription eye drops and compounded products. The company is characterized by its concentration of resources in ophthalmology, a specific therapeutic area, allowing it to rapidly expand its portfolio of commercialized products.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded about as much as usual. That is 112% of its average volume.
Next earnings report: November 9
13 days to go.
HROW keeps an operating profit but posts a net loss
Of every $100 in sales, $2.07 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +47.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $395. Peers typically go for $150.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +204.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #33 of 83 in the industry
Based on market cap of $1B.
FAQ
What kind of company is HROW?
HROW belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of HROW?
The market cap of HROW is approximately $1.1B, ranking 2,519 within its sector.
What is the 52-week high and low for HROW?
HROW has recorded a 52-week high of $54.85 and a low of $26.96.
